Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 57.14

-1.6%

2:13 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Sam Citron who wrote (9774)	12/16/2003 10:49:39 AM
From: Sam Citron	Read Replies (1) of 52153

8:21AM MEDI estimates raised at CIBC on higher FluMist sales 27.66: CIBC confirms with MedImmune that 3 mln doses of its FluMist will be made available to state governments at $20 per dose. The firm is raising its FluMist end-user sales estimates for Q4 to $85 mln from $18 mln. Its Q4 EPS estimate goes to $0.40 from $0.32. Though this news is positive for Q4 sales, the firm says it's less clear that the long-term impact will be positive as this program applies only to the 2003-2004 flu season. Furthermore, the $20 price may set a precedent which allows for little, if any, profitability. www.briefing.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next